RE:RE:Pfizer response to questions on M&A -> add value to companyFurther on the topic of ONY's expected US$8 Billion+ M&A acquisition price, J&J's top-selling immunology drug Stelara, which has brought in over $7 Billion in the first nine months of the year, is set to lose patent protection next year. And, like other big pharma companies, J&J is also extremely cash-rich, with about $34 billion on hand.